---
schema_version: "secwatch.filing_event.v1"
accession: "0001439222-23-000063"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:34:39.769346+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Agios Q1 2023: PYRUKYND revenue $5.6M, net loss improves to $81M, cash $1.0B

## Summary
- PYRUKYND net revenue of $5.6M in Q1 2023; 127 unique patients enrolled, 89 on therapy.
- Net loss of $81.0M improved from $94.8M in Q1 2022; R&D expense $67.3M, SG&A $28.4M.
- Cash, cash equivalents and marketable securities $1.0B as of March 31, 2023.
- Phase 2 sickle cell data (RISE UP) expected mid-2023; ENERGIZE/ENERGIZE-T enrollment closed.
- Appointed Jeffrey Capello to board; Paul Clancy stepping down effective June 13, 2023.

## SEC filing metadata
- accession: 0001439222-23-000063
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/0001439222-23-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/agio-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001439222-23-000063
- JSON: https://secwatch.observer/filing/0001439222-23-000063.json
- Plain text: https://secwatch.observer/filing/0001439222-23-000063.txt

## Key facts
- Earnings Releases
  AGIOS PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2023 results: revenue $5.6 million, net income $81.0 million.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $5.6 million
  - Net income: $81.0 million
  - Result: reported results
  source text: Phase 2 Portion of the RISE UP Study in Sickle Cell Disease in Mid-2023 and the Phase 3 ENERGIZE and ENERGIZE-T Studies in Thalassemia in 2024 • U.S. PYRUKYND ® Net Revenue of $5.6 Million in Q1; $1.0 Billion of Cash, Cash Equivalents and Marketable Securities as of March 31, 2023 CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1439222/000143922223000063/0001439222-23-000063-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.